Lacosamide may improve cognition in patients with focal epilepsy: EpiTrack to compare cognitive side effects of lacosamide and carbamazepine

Claudio Liguori, Francesca Izzi, Natalia Manfredi, Nicola Biagio Mercuri, Fabio Placidi

Research output: Contribution to journalArticle


Carbamazepine (CBZ) is a first generation anti-seizure drug, considered as first choice therapy in focal epilepsy but associated with cognitive side effects. Lacosamide (LCM) is a third-generation anti-seizure drug approved for treating focal epilepsy. This case series documented the comparable efficacy of LCM and CBZ as first add on treatments in patients affected by uncontrolled focal seizures. LCM showed an increase in EpiTrack scores, which measure cognitive abilities, at follow-up compared to CBZ. This preliminary data may represent the basis for future prospective studies aimed at comparing the long-term cognitive side effects of LCM and CBZ.

Original languageEnglish
Pages (from-to)35-37
Number of pages3
JournalEpilepsy and Behavior Case Reports
Publication statusPublished - Jan 1 2018



  • Carbamazepine
  • Cognition
  • EpiTrack
  • Focal epilepsy
  • Lacosamide

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Cite this